New hope for AML patients who fail venetoclax?

NCT ID NCT07471841

Recruiting now Disease control Sponsor: Timothy Pardee Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Participants take olutasidenib pills twice daily; after three cycles, azacitidine may be added if remission is not achieved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olutasidenib (with optional azacitidine)
What this could lead to: If successful, this could offer a new treatment option for AML patients whose cancer has stopped responding to venetoclax.
What could go wrong: This is a small, early-phase pilot study with only 25 participants, so results may not apply broadly. Adding azacitidine is optional and not standardized, which could affect outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDH1 MUTATION RELAPSED / REFRACTORY AML

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Medical Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.